Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) major shareholder Vision Scs F2 sold 264,072 shares of the company’s stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $9.25, for a total transaction of $2,442,666.00. Following the transaction, the insider now owns 1,460,539 shares in the company, valued at $13,509,985.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Vision Scs F2 also recently made the following trade(s):
- On Monday, May 16th, Vision Scs F2 sold 35,158 shares of Cullinan Oncology stock. The stock was sold at an average price of $11.23, for a total transaction of $394,824.34.
Shares of NASDAQ CGEM opened at $10.88 on Tuesday. The company has a market capitalization of $487.24 million, a PE ratio of -7.25 and a beta of 0.22. The firm’s 50-day moving average is $11.36 and its two-hundred day moving average is $14.45. Cullinan Oncology, Inc. has a 12-month low of $7.30 and a 12-month high of $37.66.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Credit Suisse AG lifted its stake in shares of Cullinan Oncology by 5.6% during the third quarter. Credit Suisse AG now owns 9,534 shares of the company’s stock valued at $215,000 after buying an additional 503 shares during the period. Legal & General Group Plc lifted its stake in shares of Cullinan Oncology by 13.5% during the fourth quarter. Legal & General Group Plc now owns 6,519 shares of the company’s stock valued at $101,000 after buying an additional 775 shares during the period. Deutsche Bank AG lifted its stake in shares of Cullinan Oncology by 5.4% during the fourth quarter. Deutsche Bank AG now owns 16,024 shares of the company’s stock valued at $247,000 after buying an additional 822 shares during the period. Rhumbline Advisers increased its position in Cullinan Oncology by 4.7% during the first quarter. Rhumbline Advisers now owns 32,045 shares of the company’s stock worth $336,000 after purchasing an additional 1,445 shares during the last quarter. Finally, Royal Bank of Canada increased its position in Cullinan Oncology by 209.8% during the third quarter. Royal Bank of Canada now owns 2,810 shares of the company’s stock worth $64,000 after purchasing an additional 1,903 shares during the last quarter. 93.62% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have weighed in on the stock. HC Wainwright lowered their target price on shares of Cullinan Oncology from $55.00 to $53.00 and set a “buy” rating on the stock in a research report on Friday, March 18th. Zacks Investment Research upgraded shares of Cullinan Oncology from a “sell” rating to a “hold” rating in a research report on Monday. Finally, SVB Leerink reaffirmed an “outperform” rating on shares of Cullinan Oncology in a report on Tuesday, February 8th.
Cullinan Oncology Company Profile (Get Rating)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Option Care Health Stock is Making a Healthy Pullback
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
- Concentrix: High Debt and Struggling Margins
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.